Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations:...

Area of Science:

• Oncology
• Clinical Pharmacology
• Cancer Research

Background:

• Pivotal clinical trials for advanced non-small cell lung cancer (NSCLC) often exclude patients with poor performance status (PS), limiting treatment data.
• Standard treatments for NSCLC patients with PS 2 and no targetable mutations include cytotoxic chemotherapy or carboplatin-based combinations, but evidence is insufficient.

Purpose of the Study:

• To review the current evidence on pharmacotherapy for advanced NSCLC patients with PS 2.
• To evaluate the efficacy and safety of cytotoxic chemotherapy and immune checkpoint inhibitors (ICIs) in this population.
• To discuss the heterogeneity of PS 2 and its impact on treatment strategies.

Main Methods:

• Literature review of clinical trials and relevant studies.
• Analysis of efficacy and safety data for cytotoxic agents, carboplatin-based therapies, and ICIs (anti-PD-1 antibodies, nivolumab/ipilimumab).
• Discussion of treatment outcomes in relation to PS 2 causes and patient heterogeneity.

Main Results:

• Cytotoxic chemotherapy for PS 2 NSCLC has limited efficacy and significant toxicity concerns.
• Immune checkpoint inhibitors (ICIs) offer a potentially safer alternative to chemotherapy for PS 2 patients.
• Monotherapy with anti-PD-1 antibodies may be less effective in PS 2 patients, particularly when PS is disease-related.

Conclusions:

• The optimal standard of care for advanced NSCLC with PS 2 is not yet established.
• Further research is needed to address the heterogeneity within the PS 2 population.
• Future therapeutic strategies must consider individual patient characteristics for advanced NSCLC with PS 2.